Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07374510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2026 (before its estimated September 10, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal Conjugate Vaccine. This study is planned to enroll 150 participants in total, with healthy individuals aged 2 to 59 years as participants. Among them, participants aged 18 to 59 years and 7 to 17 years will be assigned to the open-label design arm, while participants aged 4 to 6 years will be assigned to the randomized, blinded, placebo-controlled design arms.
Trial Details
NCT Number NCT07374510
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions
(from sponsor)		 Meningococcal Meningitis
Related terms Meningitis, Meningococcal
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov